Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516780 | 0.86 | HPGD (0.43) | SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL516112 | 0.85 | SLC6A2 (0.44) | SLC6A2SLC6A4ALDH1A1 | |
| SCHEMBL515947 | 0.85 | SMN1; SMN2 (0.35) | SLC6A2SLC6A4MEN1KMT2ACYP2D6 | |
| SCHEMBL516134 | 0.84 | SMN1; SMN2 (0.47) | SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL516123 | 0.84 | MEN1 (0.36) | SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL516184 | 0.83 | L3MBTL1 (0.47) | SLC6A2SLC6A4OPRM1OPRD1 | |
| SCHEMBL516139 | 0.82 | TNF (0.39) | MEN1KMT2A | |
| SCHEMBL515953 | 0.81 | OPRM1 (0.43) | SLC6A2SLC6A4OPRM1OPRD1CYP2D6 | |
| SCHEMBL515701 | 0.79 | SLC6A3 (0.43) | SLC6A2SLC6A4ALDH1A1 | |
| SCHEMBL14760363 | 0.79 | SMN1; SMN2 (0.49) | SLC6A2SLC6A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455550-B2 | Derivatives of aminocyclobutane or aminocyclobutene, their method of preparation and their use as medical products | PIERRE FABRE MEDICAMENT (FR) | 2013-06-04 | — | — | US | claimed |
| EP-2414323-B1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PF MEDICAMENT (FR) | 2013-03-13 | — | — | EP | claimed |
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PIERRE FABRE MEDICAMENT (FR) | 2012-02-02 | — | — | US | claimed |
| US-8455550-B2 | Derivatives of aminocyclobutane or aminocyclobutene, their method of preparation and their use as medical products | PIERRE FABRE MEDICAMENT (FR) | 2013-06-04 | — | — | US | disclosed |
| EP-2414323-B1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PF MEDICAMENT (FR) | 2013-03-13 | — | — | EP | disclosed |
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PIERRE FABRE MEDICAMENT (FR) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | CYP11B2, BCAT1, CYP11B1 | SLC6A2 3043/4885SLC6A4 3870/4885OPRM1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.